Changchun High-Tech Industry (000661.SZ)'s subsidiary's clinical trial application for GenSci161 Injection has been accepted.
Changchun High-Tech Industry (000661.SZ) announced that recently, its controlling subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical") received the Notice of Acceptance issued upon approval by the National Medical Products Administration, and the domestic production drug registration clinical trial application for Jinsai Pharmaceutical's GenSci161 Injection has been accepted. GenSci161 Injection is a Class 1 new therapeutic biologic independently developed by Jinsai Pharmaceutical. It is a novel fully human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cryopyrin-associated periodic syndrome (CAPS).
Changchun High-Tech Industry (000661.SZ) announced that recently, its controlling subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. ("GeneScience Pharmaceutical") received the Notice of Acceptance issued upon approval by the National Medical Products Administration, and GeneScience Pharmaceutical's domestic production drug registration clinical trial application for GenSci161 Injection has been accepted. GenSci161 Injection is a Class 1 new therapeutic biologic independently developed by GeneScience Pharmaceutical. It is a novel fully human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cryopyrin-associated periodic syndrome (CAPS).
Related Articles

EVA HOLDINGS (00838): Two subsidiaries granted term loan facilities totaling up to HK$300 million

DOMAINE POWER (00442) announces interim results, with a net loss of HK$11.503 million, an increase of 52.34% year-on-year.

NEWTREND GROUP (02573) plans to repurchase no more than HK$20 million worth of H shares.
EVA HOLDINGS (00838): Two subsidiaries granted term loan facilities totaling up to HK$300 million

DOMAINE POWER (00442) announces interim results, with a net loss of HK$11.503 million, an increase of 52.34% year-on-year.

NEWTREND GROUP (02573) plans to repurchase no more than HK$20 million worth of H shares.






